Related Experiment Videos
Enteral administration of recombinant erythropoietin to preterm infants
1Division of Neonatology, University of Utah School of Medicine, Salt Lake City, USA.
Insights
Oral recombinant erythropoietin (EPO) was not absorbed by preterm infants, failing to stimulate red blood cell production. This study suggests oral EPO is ineffective for treating anemia in premature babies.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Hematology
Background:
- Erythropoiesis is crucial for red blood cell production in infants.
- Oral administration of recombinant erythropoietin (EPO) is effective in infant rats.
- Preterm infants may benefit from EPO therapy to stimulate erythropoiesis.
Purpose of the Study:
- To test if orally administered recombinant EPO is absorbed and stimulates erythropoiesis in preterm infants.
- To compare EPO absorption and efficacy in preterm infants with infant rats.
- To evaluate the potential of oral EPO as an alternative administration route.
Main Methods:
- Six preterm infants received large doses of recombinant EPO (1000 U/kg).
- Serum EPO concentrations were measured at various time points post-administration.
- Reticulocyte count and hematocrit levels were monitored over 10 days.
Main Results:
- A small, transient increase in serum EPO was observed 2 hours post-administration.
- No significant increases in serum EPO were noted at later time points.
- No increases in reticulocyte count or hematocrit were observed, indicating a lack of erythropoietic response.
Conclusions:
- Enterally administered recombinant EPO is poorly absorbed in preterm infants.
- Oral EPO administration is not an effective method for stimulating erythropoiesis in this population.
- Subcutaneous or intravenous EPO administration remains the standard for preterm infants.
Abstract:
In six preterm infants we tested the hypothesis that, as is the case in infant rats, orally administered recombinant erythropoietin (EPO) would be absorbed and would stimulate erythropoiesis. Three study subjects were younger than 1 week old and had never been fed and three were more than 1 month old and were receiving enteral feedings totally. Two hours after the administration of large doses of EPO (1000 U/kg body weight) only a small increase in serum EPO concentrations (from 6.3 +/- 0.9 to 13.3 +/- 2.8 mU/ml, mean +/- SEM) was observed. No further increases were observed 4, 6, 12, or 24 hours after the administration. No increases in reticulocyte count or hematocrit were observed after 10 days of EPO administration. We conclude that, unlike the situation in infant rats, enterally administered recombinant EPO is not absorbed in significant amounts by human preterm infants. Therefore oral administration will not be an effective substitute for subcutaneous or intravenous EPO administration in preterm infants.